Johnson & Johnson Reports Q3 2023 Results : vimarsana.com

2023 Third-Quarter reported sales growth of 6.8% to $21.4 Billion with operational growth of 6.4%* and adjusted operational growth of 4.9%*. Operational growth excluding COVID-19 Vaccine of...

Related Keywords

Joaquin Duato , Janssen To Highlight Latest Research , Finalizes Separation Of Kenvue Inc , Johnson Announces Final Results Of Exchange , Consumer Health , Johnson , European Commission Approves , Interventional Solutions , Company Consumer Health , European Society Of Retina Specialists , Exchange Commission , European Medicines Agency Seeking Approval Of Erdafitinib , Abiomed , European Academy Of Dermatology , Janssen Highlights Latest Research , Consumer Health Company , Drug Administration Seeking Full Approval , European Medicines Agency , Chief Executive , Innovative Medicine , Infectious Diseases , General Surgery , New Announcements , Current Reports , Quarterly Reports , Annual Reports , Investor Relations , Multiple Atrial Fibrillation Ablation Products , Workflow Without Fluoroscopy , First In Class Bispecific Therapy , Heavily Pretreated Multiple Myeloma , Novel Bispecific Therapy , Refractory Multiple Myeloma , Commission Approves Reduced Dosing Frequency , Bispecific Antibody , Submits Application , First Line Treatment , Adult Patients , Advanced Non Small Cell Lung Cancer , Submits Supplemental New Drug Application , Locally Advanced , Metastatic Urothelial Carcinoma , Submits Marketing Authorisation Application , European Medicines Agency Seeking Approval , Metastatic Urothelial Cancer , Abiraterone Acetate , First And Only Dual Action Tablet , Highlight Latest Research , Nipocalimab Clinical Development Program , Address Unmet Need , Myasthenia Gravis , Define New Standards , Solid Tumor Cancers , Transformative Data Planned , Severely Active Crohn , Highlights Latest Research , Investigational Targeted Oral Peptide , Isevere Plaque Psoriasis , European Academy , Meets Primary Endpoint Resulting , Statistically Significant , Clinically Meaningful Improvement , Progression Free Survival , Lazertinib Versus Osimertinib , Mutated Non Small Cell Lung Cancer , Meets Dual Primary Endpoint Resulting , Disease Progression , Previously Treated , Mutated Advanced Non Small Cell Lung Cancer , Highlight Latest Advances , Retina Portfolio , European Society , Retina Specialists , Webster Launches , Complex Cardiac Arrhythmias , Johnson Announces Final Results , Exchange Offer , Finalizes Separation , Johnson Announces Updated Financials , Following Completion , Kenvue Separation , Johnson Marks New Era , Global Healthcare Company , Updated Visual Identity , Shares Outstanding , Euro Average Rate , Average Shares Outstanding , Investors Concerning Forward Looking Statements , Private Securities Litigation Reform Act , New Consumer Health Company , Annual Report , Note Regarding Forward Looking , Consolidated Statement , Millions Except Per Share Figures , Discontinued Operations , Continuing Operations , Millions Except Per Share Data , Asset Amortization , Net Earnings , Medical Device Regulation , European Medical Devices Directive , Sales Reconciliation , Before Tax , Income Before Tax , Segment From Continuing , Markets ,